XM tidak menyediakan perkhidmatan kepada penduduk Amerika Syarikat.

Abu Dhabi's ADNOC to buy German chemicals company Covestro for $18 bln



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>UPDATE 3-Abu Dhabi's ADNOC to buy German chemicals company Covestro for $18 bln</title></head><body>

ADNOC to pay 62 euros a Covestro share, including 3 bln in debt

To buy additional 1.2 bln euros worth of new shares in Covestro

Covestro shares jump 3.7% to a three-year high

Deal could fuel debate of foreign takeovers of German companies

Adds shares in paragraph 5, capital threshold in paragraph 9, background on Germany from paragraph 10

By Ludwig Burger

BERLIN, Oct 1 (Reuters) -Abu Dhabi's ADNOC has agreed to buy German chemicals producer Covestro 1COV.DE for 15.9 billion euros ($18 billion) including debt, the state oil giant said on Tuesday, representing its largest acquisition to date.

The deal is one of the biggest foreign takeovers by a Gulf state as Abu Dhabi and other countries in the region seek to reduce their economies' heavy dependence on oil in the face of the global energy transition.

It follows protracted negotiations between the two companies and will see ADNOC pay 62 euros per Covestro share, equal to 14.7 billion euros including about 3 billion euros in debt.

ADNOC added it would also buy 1.17 billion euros worth of new shares in Covestro, a former Bayer BAYGn.DE unit, from a capital increase to improve funding of the takeover target.

Covestro shares jumped 3.7% to a three-year high of 58 euros.

The deal is a cornerstone for ADNOC's plans to grow its petrochemicals business along with gas and renewable energy.

ADNOC has also been in talks with Austria's OMV for more than a year to merge their petrochemical joint ventures Borealis and Borouge. ADNOC took a 24.9% stake in OMV from Abu Dhabi sovereign fund Mubadala in February.

Covestro, which makes plastics and chemicals for the automotive, construction and engineering sectors, was created in 2015 after being spun off from Bayer. It opened its books to ADNOC in June - a year after ADNOC's initial interest was reported.

The public takeover offer will be subject to a minimum acceptance threshold of 50% plus one share of Covestro's capital.


WIDE-RANGING CONCESSIONS

The deal could reignite a debate about Germany's blue-chip companies facing foreign takeover overtures because of a weak economy.

Italy's UniCredit CRDI.MI is seeking to merge with Commerzbank CBKG.DE after snapping up a stake in its German rival, drawing criticism from Germany's political establishment, who want to keep the lender independent.

Covestro, however, said it won wide-ranging concessions to limit the buyer's control of the company.

Half of the seats on its supervisory board would continue to be held by labour representatives, as is the norm at German listed companies, and two members of the board's shareholder representatives will remain independent of ADNOC.

ADNOC pledged not to sell, close or significantly reduce Covestro's business activities and it would "protect Covestro's technology and intellectual property", Covestro said.

It added that its management board would stay in charge of management and strategic direction.

Covestro reported a net loss of 72 million euros in the first six months of the year, compared with 46 million euros profit in the previous year.

The agreement illustrates an increase in dealmaking between the Middle East and Europe, as Gulf investors are drawn to company valuations that lag those in the United States, an easier regulatory backdrop for buyers from the region, and where investment needs make them more welcome, advisers and analysts have told Reuters.

It is the Middle East's second biggest acquisition after Israel's Teva Pharmaceuticals' acquisition of Allergan's generic drugs business for around $40 billion in 2015, according to Dealogic data.


($1 = 0.8990 euros)



Reporting by Ludwig Burger
Additional reporting by Friederike Heine
Editing by David Goodman and Emelia Sithole-Matarise

</body></html>

Penafian: Entiti XM Group menyediakan perkhidmatan pelaksanaan sahaja dan akses ke Kemudahan Dagangan Atas Talian, yang membolehkan sesorang melihat dan/atau menggunakan kandungan yang ada di dalam atau melalui laman web, tidak bertujuan untuk mengubah atau memperluas, juga tidak mengubah atau mengembangkannya. Akses dan penggunaan tersebut tertakluk kepada: (i) Terma dan Syarat; (ii) Amaran Risiko; dan Penafian Penuh. Oleh itu, kandungan sedemikian disediakan tidak lebih dari sekadar maklumat umum. Terutamanya, perlu diketahui bahawa kandungan Kemudahan Dagangan Atas Talian bukan permintaan, atau tawaran untuk melakukan transaksi dalam pasaran kewangan. Berdagang dalam mana-mana pasaran kewangan melibatkan tahap risiko yang besar terhadap modal anda.

Semua bahan yang diterbitkan di Kemudahan Dagangan Atas Talian kami bertujuan hanya untuk tujuan pendidikan/maklumat dan tidak mengandungi – dan tidak boleh dianggap mengandungi nasihat kewangan, cukai pelaburan atau dagangan dan cadangan, atau rekod harga dagangan kami, atau tawaran, atau permintaan untuk suatu transaksi dalam sebarang instrumen kewangan atau promosi kewangan yang tidak diminta kepada anda.

Sebarang kandungan pihak ketiga serta kandungan yang disediakan oleh XM, seperti pendapat, berita, penyelidikan, analisis, harga, maklumat lain atau pautan ke laman web pihak ketiga yang terdapat dalam laman web ini disediakan berdasarkan "seadanya" sebagai ulasan pasaran umum dan bukanlah nasihat pelaburan. Sesuai dengan apa-apa kandungan yang ditafsir sebagai penyelidikan pelaburan, anda mestilah ambil perhatian dan menerima bahawa kandungan tersebut tidak bertujuan dan tidak sediakan berdasarkan keperluan undang-undang yang direka untuk mempromosikan penyelidikan pelaburan bebas dan oleh itu, ia dianggap sebagai komunikasi pemasaran di bawah peraturan dan undang-undang yang berkaitan. SIla pastikan bahawa anda telah membaca dan memahami Notifikasi mengenai Penyelidikan Pelaburan Bukan Bebas dan Amaran Risiko mengenai maklumat di atas yang boleh diakses di sini.

Amaran Risiko: Modal anda dalam risiko. Produk yang berleveraj mungkin tidak sesuai untuk semua individu. Sila pertimbangkan Pendedahan Risiko kami.